Table 4.
Analyses of the associations between treatment aspects and survival status in 160 critically ill ILD patients.
| survivors (n = 58) | nonsurvivors (n = 102) | P value | |
|---|---|---|---|
| Immunosuppressive agents | 25 (43.1%) | 33 (32.4%) | 0.174 |
| Conventional oxygen therapy | 53 (96.4%)b | 70 (69.3%)c | 0.000 |
| Non-invasive ventilator | 12 (21.8%)b | 64 (63.4%)c | 0.000 |
| Invasive ventilator | 0 (0.0%)b | 12 (11.9%)c | 0.008 |
| Sedative | 14 (24.1%) | 66 (64.7%) | 0.000 |
| High-dose glucocorticoid (>1 mg/kg/d) therapy | 32 (55.2%) | 74 (72.5%) | 0.025 |
| Beta lactam antibiotic | 50 (86.2%) | 67 (65.7%) | 0.005 |
| Carbapenem | 20 (34.5%) | 62 (60.8%) | 0.001 |
| Sulfonamide | 32 (55.2%) | 68 (66.7%) | 0.149 |
| Quinolones | 20 (34.5%) | 29 (28.4%) | 0.425 |
| Glycopeptide | 1 (1.7%) | 13 (12.7%) | 0.018 |
| Macrolides | 0 (0.0%) | 2 (2.0%) | 0.283 |
| Antiviral therapy | 36 (62.1%) | 69 (67.6%) | 0.475 |
| Antifungal therapy | 21 (36.2%) | 58 (56.9%) | 0.012 |
b: n = 55, c: n = 101.